Please use this identifier to cite or link to this item:
Title: Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.
Austin Authors: Chia, Puey Ling ;Mitchell, Paul L R ;Dobrovic, Alexander ;John, Thomas 
Affiliation: School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Pathology, University of Melbourne, Victoria, Australia
Ludwig Institute for Cancer Research, Austin Health, Victoria, Australia
Issue Date: 20-Nov-2014
Publication information: Clinical Epidemiology 2014; 6(): 423-32
Abstract: Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.
DOI: 10.2147/CLEP.S69718
Journal: Clinical epidemiology
PubMed URL: 25429239
Type: Journal Article
Subjects: anaplastic lymphoma kinase (ALK)
gene rearrangements
kinase inhibitors
lung adenocarcinoma
lung cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 13, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.